Abingworth Appoints New Partner
This article was originally published in Scrip
Shelley Chu has joined international investment group, Abingworth, as a partner and will source and manage deals across various therapeutic areas and stages of development. Chu joins the company from Gilead Sciences where she led business development in oncology, immunotherapy and hepatitis B, as well as R&D Strategy. Previously she was principal at Frazier Healthcare Ventures.
Register for our free email digests: